Engineered immune cells take on tough blood cancers in early trial
NCT ID NCT03233854
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a treatment that uses a patient's own immune cells, modified to recognize and attack cancer cells, for adults with B-cell blood cancers that have returned or not responded to standard therapy. The treatment is given with chemotherapy and sometimes an immune-boosting drug. The main goals are to check safety and find the best dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University, School of Medicine
Palo Alto, California, 94304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chemo-Antibody combo beat a tough leukemia?
- Could a simple drug tame the dangerous side effects of CAR-T cancer therapy?
- Blood test may end painful bone marrow biopsies for myeloma patients
- New drug cocktail aims to improve remission in older leukemia patients
- Real-World watch on ph+ leukemia treatments aims to uncover best paths to remission
- Engineered immune cells take aim at tough childhood leukemia